NDA 7-073/S-113

APR 1 8 2000

Pharmacia & Upjohn Company
Attention: Gregory A. Brier
Regulatory Manager-Marketed Products
7000 Portage Road
0633-298-113
Kalamazoo, MI 49001

Dear Mr. Brier:

Please refer to your supplemental new drug application dated October 29, 1999, received November 1, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Azulfidine (sulfasalazine) Tablets and EN-tabs Tablets.

This "Changes Being Effected" supplemental new drug application provides for revision of the 300 count Azulfidine EN-tabs package insert (ADVERSE REACTIONS section, Hypersensitivity Reactions subsection) to include the phrase "fulminant hepatitis, sometimes leading to liver transplantation" in response to our December 2, 1998 letter. Your submission stated October 6, 1999 as the implementation date for the change.

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert and immediate container labels submitted October 29, 1999). Accordingly, the supplemental application is approved effective on the date of this letter.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockvllle, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

We note that Azulfidine EN-tabs are also available in a 100 count bottle. According to your October 29, 1999 submission, revised 100 count final printed labeling will not be available until September 2000. At that time, please submit a separate supplement for the 100 count Azulfidine EN-tabs labeling that provides for the revision described above. Please submit twenty copies of

the final printed labeling, ten of which are individually mounted on heavy weight paper or similar material, as a “Supplement - Changes Being Effected”. Please incorporate all previous revisions as reflected in the most recently approved package insert. To facilitate review of your submission, please provide a highlighted or marked-up copy that shows the changes that are being made.

If you have any questions, call Melodi McNeil, Regulatory Health Project Manager, at (301) 827-7310.

Sincerely,

Lilia Talarico, M.D.
Director
Division of Gastrointestinal and Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Hypersensitivity reactions: erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, epidermal necrolysis (Lyell's syndrome) with corneal damage, anaphylaxis, serum sickness syndrome, pneumonitis with or without eosinophilia, vasculitis, fibrosing alveolitis, pleuritis, pericarditis with or without tamponade, allergic myocarditis, polyarteritis nodosa, lupus erythematosus-like syndrome, hepatitis and hepatic necrosis with or without immune complexes, fulminant hepatitis, sometimes leading to liver transplantation, parapsorlasis varioliformis acuta (Mucha-Haberman syndrome), rhabdomyolysis, photosensitization, arthralgia, periorbital edema, conjunctival and scleral injection, and alopecia.